000283112 001__ 283112
000283112 005__ 20260103103703.0
000283112 0247_ $$2doi$$a10.1002/alz70861_108410
000283112 0247_ $$2ISSN$$a1552-5260
000283112 0247_ $$2ISSN$$a1552-5279
000283112 037__ $$aDZNE-2026-00008
000283112 082__ $$a610
000283112 1001_ $$aZhunussova, Alina$$b0
000283112 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283112 245__ $$aChanges in Task‐evoked Pupil Dilation during Emotional Memory as a Marker of Noradrenergic Function in Healthy Aging and MCI
000283112 260__ $$c2025
000283112 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767354688_32513
000283112 3367_ $$033$$2EndNote$$aConference Paper
000283112 3367_ $$2BibTeX$$aINPROCEEDINGS
000283112 3367_ $$2DRIVER$$aconferenceObject
000283112 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283112 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283112 3367_ $$2ORCID$$aOTHER
000283112 520__ $$aBackground:Improved memory for negative events is supported by the locus coeruleus-noradrenergic (LC-NA) system. As the LC is one of the first structures exhibiting tau pathologies in AD, in vivo markers for structural and functional changes in the LC are required. We used pupil dilation (PD) as a non-exclusive and indirect but easy and non-invasive way to acquire a measure of LC-NA activity. We investigated whether PD can serve as a marker of alteration in noradrenergic function in mild cognitive impairment (MCI) during emotional memory.Method:The emotional memory task was completed by 83 participants (28 younger adults (YAs), 25 older adults (OAs), and 30 patients with MCI) during eye-tracking recordings. In the incidental encoding task, participants were shown a neutral or negative indoor or outdoor scene and were instructed to categorize it as either indoor or outdoor. In the immediate recognition test and the delayed recognition test (6 hours later), participants were instructed to classify the pictures as new or old.Result:PD was larger for emotional as compared to neutral scenes in YAs and OAs but overall increased in MCI patients, regardless of scene type, suggesting a deficiency in emotional regulation. The increase in emotional reactivity in MCI does not translate into improved emotional memory; as expected, emotional scenes were better remembered than neutral scenes, with MCI patients showing worse memory than YAs or OAs.Conclusion:PD can be reliably measured in patients with MCI. Moreover, changes in task-evoked PD during an emotional memory task can reveal differences between healthy aging and MCI in emotional reactivity.
000283112 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283112 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283112 7001_ $$aLoane, Clare$$b1
000283112 7001_ $$aKurt, Elif$$b2
000283112 7001_ $$aFemminella, Grazia Daniela$$b3
000283112 7001_ $$aLenzoni, Sabrina$$b4
000283112 7001_ $$aDuckett, Millie$$b5
000283112 7001_ $$aCallaghan, Martina F$$b6
000283112 7001_ $$aWeiskopf, Nikolaus$$b7
000283112 7001_ $$aDolan, Raymond J$$b8
000283112 7001_ $$aHoward, Robert$$b9
000283112 7001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b10$$udzne
000283112 7001_ $$0P:(DE-2719)2811927$$aHämmerer, Dorothea$$b11$$eLast author$$udzne
000283112 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70861_108410$$gVol. 21, no. S7, p. e108410$$nS7$$pe108410$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283112 8564_ $$uhttps://pub.dzne.de/record/283112/files/DZNE-2026-00008.pdf$$yOpenAccess
000283112 8564_ $$uhttps://pub.dzne.de/record/283112/files/DZNE-2026-00008.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283112 909CO $$ooai:pub.dzne.de:283112$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283112 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000283112 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811927$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000283112 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283112 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283112 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283112 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283112 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283112 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283112 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283112 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283112 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283112 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283112 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283112 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283112 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x0
000283112 980__ $$aabstract
000283112 980__ $$aVDB
000283112 980__ $$aUNRESTRICTED
000283112 980__ $$ajournal
000283112 980__ $$aI:(DE-2719)5000006
000283112 9801_ $$aFullTexts